Involvement of the urokinase kringle domain in lipopolysaccharide-induced acute lung injury

被引:34
作者
Wang, Xue-Qing
Bdeir, Khalil
Yarovoi, Sergei
Cines, Douglas B.
Fang, Wenfeng
Abraham, Edward
机构
[1] Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA
[2] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[3] Univ Alabama, Dept Med, Birmingham, AL 35294 USA
[4] Chang Gung Univ, Coll Med, Div Pulm & Crit Care, Chang Gung Mem Hosp,Kaohsiung Med Ctr, Kaohsiung, Taiwan
关键词
NF-KAPPA-B; PLASMINOGEN-ACTIVATOR INHIBITOR-1; INDUCED NEUTROPHIL ACTIVATION; CYTOKINE EXPRESSION; PNEUMOCOCCAL PNEUMONIA; IN-VIVO; RECEPTOR; HEMORRHAGE; ENDOTOXEMIA; COAGULATION;
D O I
10.4049/jimmunol.177.8.5550
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Urokinase plasminogen activator (uPA) plays a major role in fibrinolytic processes and also can potentiate LPS-induced neutrophil activation through interactions with its kringle domain (KD). To investigate the role of the uPA KD in modulating acute inflammatory processes in vivo, we cloned and then developed Abs to the murine uPA KD. Increased pulmonary expression of uPA and the uPA KD was present in the lungs after LPS exposure. Administration of anti-kringle Abs diminished LPS-induced upregulation of uPA and uPA KD in the lungs, and also decreased the severity of LPS-induced acute lung injury, as determined by development of lung edema, pulmonary neutrophil accumulation, histology, and lung IL-6, MIP-2, and TNF-alpha cytokine levels. These proinflammatory effects of the uPA KD appeared to be mediated through activation of Akt and NF-kappa B. The present studies indicate that the uPA KD plays a major role in the development of TLR4-mediated acute inflammatory processes, including lung injury. Blockade of the uPA KD may prevent the development or ameliorate the severity of acute lung injury induced through TLR4-dependent mechanisms, such as would occur in the setting of Gram-negative pulmonary or systemic infection.
引用
收藏
页码:5550 / 5557
页数:8
相关论文
共 45 条
[1]   PHOSPHATIDIC-ACID SIGNALING MEDIATES LUNG CYTOKINE EXPRESSION AND LUNG INFLAMMATORY INJURY AFTER HEMORRHAGE IN MICE [J].
ABRAHAM, E ;
BURSTEN, S ;
SHENKAR, R ;
ALLBEE, J ;
TUDER, R ;
WOODSON, P ;
GUIDOT, DM ;
RICE, G ;
SINGER, JW ;
REPINE, JE .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (02) :569-575
[2]  
ABRAHAM E, 1994, CLIN EXP IMMUNOL, V98, P29
[3]   Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation [J].
Abraham, E ;
Gyetko, MR ;
Kuhn, K ;
Arcaroli, J ;
Strassheim, D ;
Park, JS ;
Shetty, S ;
Idell, S .
JOURNAL OF IMMUNOLOGY, 2003, 170 (11) :5644-5651
[4]   Cutting edge: HMG-1 as a mediator of acute lung inflammation [J].
Abraham, E ;
Arcaroli, J ;
Carmody, A ;
Wang, HC ;
Tracey, KJ .
JOURNAL OF IMMUNOLOGY, 2000, 165 (06) :2950-2954
[5]   Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury [J].
Abraham, E ;
Carmody, A ;
Shenkar, R ;
Arcaroli, J .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2000, 279 (06) :L1137-L1145
[6]   Regulatory roles for CD14 and phosphatidylinositol in the signaling via toll-like receptor 4-MD-2 [J].
Akashi, S ;
Ogata, H ;
Kirikae, F ;
Kirikae, T ;
Kawasaki, K ;
Nishijima, M ;
Shimazu, R ;
Nagai, Y ;
Fukudome, K ;
Kimoto, M ;
Miyake, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 268 (01) :172-177
[7]  
Arcaroli J, 2002, J LEUKOCYTE BIOL, V72, P571
[8]   Role of p38 MAP kinase in the development of acute lung injury [J].
Arcaroli, J ;
Yum, HK ;
Kupfner, J ;
Park, JS ;
Yang, KY ;
Abraham, E .
CLINICAL IMMUNOLOGY, 2001, 101 (02) :211-219
[9]   Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-κB [J].
Asehnoune, K ;
Strassheim, D ;
Mitra, S ;
Kim, JY ;
Abraham, E .
JOURNAL OF IMMUNOLOGY, 2004, 172 (04) :2522-2529
[10]   Lipopolysaccharide-induced lung injury in mice. I. Concomitant evaluation of inflammatory cells and haemorrhagic lung damage [J].
Asti, C ;
Ruggieri, V ;
Porzio, S ;
Chiusaroli, R ;
Melillo, G ;
Caselli, GF .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2000, 13 (02) :61-69